WEDNESDAY, May 11, 2005 (HealthDay News) -- An investigational drug called DG-031 appears to lower inflammatory markers associated with increased heart attack risk, according to a preliminary study in the May 11 issue of the Journal of the American Medical Association.
The study found that the use of DG-031 to inhibit a specific protein, called 5-lipoxygenase activating protein (FLAP), reduced levels of these inflammatory markers in people with certain genetic variants that increase their risk of heart attack.
The study was sponsored by Iceland-based deCODE genetics Inc.
Researchers are currently planning a study to determine whether DG-031 actually reduces heart attack risk.
The American Heart Association has more about heart attack.